A similar hypothesis has been advanced in cervical carcinoma, for which increased cDDP-resistance has been observed in association with reduction of activation of the MEK to ERK2 pathway (in the presence of a MEK1-selective inhibitor, 2’-amino-3’-methoxyflavone) and involving, at least in part, an increase of NF-κB activation [50]. The gene discussed is NFKB1; the disease is cervical carcinoma.